Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review

Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review

<p>Abstract</p> <p>Background</p> <p>Cancer and its therapies increase the risk of venous thromboembolism. Compared to patients without cancer, patients with cancer anticoagulated for venous thromboembolism are more likely to develop recurrent thrombotic events and majo...

Full description

Bibliographic Details
Main Authors:	Sperati Francesca, Terrenato Irene, Rohilla Sandeep, Barba Maddalena, Akl Elie A, Muti Paola, Schünemann Holger J
Format:	Article
Language:	English
Published:	BMC 2008-07-01
Series:	Journal of Experimental & Clinical Cancer Research
Online Access:	http://www.jeccr.com/content/27/1/21

Similar Items

Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism
by: Isabel Elías, et al.
Published: (2016-05-01)

Low-molecular-weight heparins in the treatment of venous thromboembolism
by: Huisman Menno V, et al.
Published: (2000-08-01)

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
by: Patel R
Published: (2016-05-01)

Why differentiate low molecular weight heparins for venous thromboembolism?
by: Walenga Jeanine M, et al.
Published: (2007-06-01)

An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation
by: Akl Elie A, et al.
Published: (2010-03-01)

Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism
by: Maodi Xu, et al.
Published: (2018-09-01)

Heparin versus Danaproid for Prevention of Venous Thromboembolism after Hip Surgery
by: J Nakase, et al.
Published: (2009-04-01)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
by: Alex C Spyropoulos, et al.
Published: (2008-06-01)

Spontaneous Heparin-Induced Thrombocytopenia and Venous Thromboembolism following Total Knee Arthroplasty
by: Kevin Baker, et al.
Published: (2017-01-01)

Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review
by: Yosuico Victor, et al.
Published: (2008-05-01)

Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism
by: Samuel Adediran, et al.
Published: (2017-01-01)

Prescribing of Low-Molecular-Weight Heparin and Warfarin in Patients with Acute Venous Thromboembolism and Active Cancer
by: Steward, David W., et al.
Published: (2014)

Modern low-molecular-weight heparins in the prevention and treatment of venous thromboembolic complications in oncourologic patients
by: N. V. Vorobyev, et al.
Published: (2018-11-01)

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
by: Alannah Smrke, et al.
Published: (2017-08-01)

Low molecular weight heparin in one or two doses for the initial treatment of venous thromboembolic disease?
by: Juan Pablo Albornoz, et al.
Published: (2015-12-01)

Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline
by: Fahad Al-Hameed, et al.
Published: (2015-03-01)

Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
by: Prandoni Paolo
Published: (2008-09-01)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
by: Pineo GF, et al.
Published: (2012-04-01)

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
by: Abdel-Razeq H, et al.
Published: (2011-06-01)

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis
by: Dranitsaris G, et al.
Published: (2017-01-01)

VENOUS THROMBOEMBOLISM IN RELATION TO OVARIAN HYPERSTIMULATION SYNDROME: AN APPROACH TO DETERMINING THE LOW-MOLECULAR-WEIGHT-HEPARIN DOSES AND ACTIVITY
by: I. E. Zazerskaya, et al.
Published: (2016-06-01)

Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY
by: Abletshauser Claudia, et al.
Published: (2011-07-01)

What′s new in emergencies, trauma, and shock? Heparin in severe traumatic brain injury: Beyond venous thromboembolism prevention?
by: Luca Masotti, et al.
Published: (2014-01-01)

Osteoporosis and venous thromboembolism
by: Irina Aleksandrovna Baranova, et al.
Published: (2011-02-01)

Venous thromboembolic complications
by: G. G. Khubulava, et al.
Published: (2019-02-01)

THALASSEMIA AND VENOUS THROMBOEMBOLISM
by: Khaled M. Musallam, et al.
Published: (2011-01-01)

Venous thromboembolism and pregnancy
by: Maristella D&rsquo;Uva, et al.
Published: (2010-03-01)

Venous thromboembolism in children
by: Helena Pereira, et al.
Published: (2016-02-01)

Venous Thromboembolism in Adolescents
by: Aneta Samková, et al.
Published: (2012-01-01)

Venous thromboembolism: The intricacies
by: Dutta T, et al.
Published: (2009-01-01)

THALASSEMIA AND VENOUS THROMBOEMBOLISM
by: Julien Succar, et al.
Published: (2011-05-01)

Neonatal Venous Thromboembolism
by: Kristina M. Haley
Published: (2017-06-01)

Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
by: Wei Wang, et al.
Published: (2020-02-01)

The role of heparin in thromboembolic complications following carotid endarterectomy
by: McMahon, Gregory Scott
Published: (2011)

Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism
by: Keita I, et al.
Published: (2017-09-01)

Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes.
by: Torben Bjerregaard Larsen, et al.
Published: (2014-01-01)

Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register
by: Daniela Poli, et al.
Published: (2020-11-01)

Venous Thromboembolism in Pediatric Orthopedics
by: Amir Reza Vafaee, et al.
Published: (2016-05-01)

Venous thromboembolic disease in obstetrics
by: Rivas- Perdomo Édgar, et al.
Published: (2012-06-01)

The importante of profilaxis in venous thromboembolism
by: Marcelo Calil Burihan
Published: (2020-11-01)